NEW! PSORIASIS PRECLINICAL EVALUATION PLATFORM Biomedcode has recently developed an Imiquimod-based Psoriasis preclinical evaluation platform. INDICATIONS • Rapid and convenient model for the evaluation of new therapies targeting psoriasis • Fast screening of biologics and small molecules • Evaluation of topical application formulations • Evaluation of humanized therapeutics

IMIQUIMOD-INDUCED PSORIASIS Topical application of Aldara (5% Imiquimod) results in the fast development of psoriasis-like lesions. The pathology is similar to human disease characterized by skin erythema, scaling and thickness and at the histopathological level hyperproliferation of keratinocytes and inflammatory infiltrates. DISEASE CAN BE INDUCED IN • wild type animals • human transgenic animals READ-OUTS •In vivo scoring •Spleen Weight •Histopathology

0

1

2

3

4

5

6

1

Ηis

top

ath

olo

gica

l sco

re

0,000

0,002

0,004

0,006

0,008

0,010

0,012

1

Sple

en w

eigh

t/B

od

y w

eigh

t

About Us Biomedcode is a highly innovative CRO that provides preclinical drug evaluation services offering scientific consultation and custom-tailored solutions for the optimized evaluation of novel and biosimilar pharmaceuticals. Biomedcode offers a diverse array of state-of-the-art preclinical evaluation platforms based on a unique collection of mouse models that closely mimic human inflammatory diseases. Biomedcode’s human TNF transgenic models were instrumental in providing the preclinical rationale for the development of anti-TNF therapies in arthritis.

Normal skin Psoriatic skin

0,000

0,002

0,004

0,006

0,008

0,010

0,012

1

Sple

en w

eigh

t/B

od

y w

eigh

t

Aldara

Aldara+Clobetasol

Naïve

Newsletter Issue: January 2014

www.biomedcode.com

HUMANIZED MODELS

hTNF hTNFR2hTNFR1KI IL17a

SPONTANEOUSArthritis (hTNF/hTNFR1)

• Tg197• hTNFR1Tg197• Tg3647• Tg5453• TNF DARE

IntestinalInflammation (TNF)

TNF DARE

INDUCEDArthritisCAIA

Intestinal InflammationTNBS colitis

Multiple SclerosisEAE

Psoriasis (NEW!)IMQ model

LPS, LPS/D-gal

DISEASE MODELS

0,2

0,4

0,6

0,8

1,0

1,2

1,4

D2 D3 D4 D5

Skin

th

ickn

ess